Dr Cedric Cui
Postdoctoral Research Fellow
School of Biomedical Sciences
Dr Cui joined the Neuroinflammation Lab in late 2018 as a PhD student, under the supervision of Professor Trent Woodruff. His research project focused on the preclinical development of C5aR1 antagonists for the treatment of various inflammatory diseases, including inflammatory bowel disease (IBD). In 2023, he was appointed as a postdoctoral research fellow under the supervision of Dr John Lee. His current project focuses on investigating new therapeutics for neurodegenerative diseases. Dr Cui’s recent experience includes working with LC-MS/MS, QdToF, and timsToF fleX-MALDI-2, for conducting pharmacokinetics, neurotransmitter, and spatial metabolomic and lipidomic studies.
Journal Articles
McDonald, Tanya S., Cui, Cedric S., Lerskiatiphanich, Titaya, Marallag, Jianina and Lee, John D. (2025). Metabolic rate and insulin-independent glucose uptake increase in a TDP-43Q331K mouse model of amyotrophic lateral sclerosis. Heliyon, 11 (3) e42482, 1-13. doi: 10.1016/j.heliyon.2025.e42482
Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria X., Whittaker, Andrew K., Xu, Zhi Ping, Smith, Maree T., Woodruff, Trent M. and Han, Felicity Y (2022). Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacy. Advanced Therapeutics, 5 (12) 2200109, 2200109. doi: 10.1002/adtp.202200109
Cui, Cedric S., Kumar, Vinod, Gorman, Declan M., Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy. ACS Pharmacology and Translational Science, 5 (1) acsptsci.1c00227, 41-51. doi: 10.1021/acsptsci.1c00227
Xu, Weizhi, Maqbool, Faheem, Kumar, Vinod, Falconer, James R., Cui, Cedric S., Woodruff, Trent M., Borges, Karin, Whittaker, Andrew K., Smith, Maree T. and Han, Felicity Y. (2021). Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 12 (10), 2518-2526. doi: 10.1007/s13346-021-01093-3
Gorman, Declan M., Li, Xaria X., Payne, Colton D., Cui, Cedric S., Lee, John D., Rosengren, K. Johan, Woodruff, Trent M. and Clark, Richard J. (2021). Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo. ACS Pharmacology and Translational Science, 4 (6) acsptsci.1c00199, 1808-1817. doi: 10.1021/acsptsci.1c00199
Gorman, Declan M., Li, Xaria X., Lee, John D., Fung, Jenny N., Cui, Cedric S., Lee, Han Siean, Rolfe, Barbara E., Woodruff, Trent M. and Clark, Richard J. (2021). Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 64 (22) acs.jmedchem.1c01174, 16598-16608. doi: 10.1021/acs.jmedchem.1c01174
Pandey, Shubhi, Kumari, Punita, Baidya, Mithu, Kise, Ryoji, Cao, Yubo, Dwivedi-Agnihotri, Hemlata, Banerjee, Ramanuj, Li, Xaria X., Cui, Cedric S., Lee, John D., Kawakami, Kouki, Maharana, Jagannath, Ranjan, Ashutosh, Chaturvedi, Madhu, Jhingan, Gagan Deep, Laporte, Stéphane A., Woodruff, Trent M., Inoue, Asuka and Shukla, Arun K. (2021). Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Molecular Cell, 81 (22), 4605-4621.e11. doi: 10.1016/j.molcel.2021.09.007
Han, Felicity Y., Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria, Jiang, Xingyu, Woodruff, Trent M., Whittaker, Andrew K. and Smith, Maree T. (2021). Optimisation of a microfluidic method for the delivery of a small peptide. Pharmaceutics, 13 (9) 1505, 1505. doi: 10.3390/pharmaceutics13091505
Chakraborty, Rituparna, Chandra, Janin, Cui, Shuai, Tolley, Lynn, Cooper, Matthew A., Kendall, Mark and Frazer, Ian H. (2017). CD8+ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury. Experimental Dermatology, 27 (1), 71-79. doi: 10.1111/exd.13436
Conference Papers
Cui, Cedric, Lee, John and Woodruff, Trent (2024). Colon-targeted complement C5aR1 inhibition using pH-sensitive nanoparticles ameliorates experimental colitis. 19th European Meeting on Complement in Human Diseases, Lübeck, Germany, 2-6 September 2024. Weinheim, Germany: Wiley-VCH.
Clark, Richard, Gorman, Declan, Li, Xaria, Dent, Joshua, Cui, Cedric, Lee, Han Siean, Fung, Jenny, Lee, John, Rosengren, K. Johan and Woodruff, Trent (2024). Development of novel peptide ligands with improved selectivity and pharmacological properties for complement system receptors. 37th European Peptide Symposium 14th International Peptide Symposium, Florence, Italy, 25-29 August 2024. Oxford, United Kingdom: John Wiley & Sons.
Thesis
Cui, Shuai (2022). Preclinical development of complement C5aR1 antagonists for the treatment of inflammatory bowel disease. PhD Thesis, School of Biomedical Sciences, The University of Queensland. doi: 10.14264/3a8be04